Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | ACS Chemical Neuroscience
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | ACS Chemical Neuroscience
FFN200 dihydrochloride | VMAT2 Substrate | MedChemExpress
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors - LiverTox - NCBI Bookshelf
PDF) Emulating proton-induced conformational changes in the Vesicular monoamine transporter VMAT2 by mutagenesis
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | ACS Chemical Neuroscience
Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size | Journal of Neuroscience
VMAT2 inhibitors for the treatment of hyperkinetic movement disorders - ScienceDirect
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | ACS Chemical Neuroscience
Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size | Journal of Neuroscience
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | ACS Chemical Neuroscience
Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors - LiverTox - NCBI Bookshelf
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | ACS Chemical Neuroscience
Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine in: Journal of Endocrinology Volume 198 Issue 1 (2008)
Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine in: Journal of Endocrinology Volume 198 Issue 1 (2008)
Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size | Journal of Neuroscience
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | ACS Chemical Neuroscience
Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine in: Journal of Endocrinology Volume 198 Issue 1 (2008)
Tetrabenazine (Ro 1-9569) | VMAT2 Inhibitor | MedChemExpress
Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size | Journal of Neuroscience
Frontiers | Elucidating the Relationship Between Diabetes Mellitus and Parkinson's Disease Using 18F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | ACS Chemical Neuroscience
VMAT2 gene expression and function as it applies to imaging β-cell mass | SpringerLink
Inhibitory co-transmission from midbrain dopamine neurons relies on presynaptic GABA uptake - ScienceDirect
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? | CNS Spectrums | Cambridge Core
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? | CNS Spectrums | Cambridge Core
